News | March 24, 2025
Briefs: Alembic Pharmaceuticals and Shelter Pharma
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Subscribe To Our Newsletter & Stay Updated
